Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG)

Peptides

Volumn 18, Issue 8, 1997, Pages 1209-1215

  Mishra, Ram K ^a   Marcotte, Eric R ^a   Chugh, Anita ^a   Barlas, Cia ^a   Whan, Deborah ^a   Johnson, Rodney L ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

6 OHDA; Apomorphine; Parkinson's disease; PLG; Supersensitivity

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 [(2 PYRROLIDINYLCARBONYL)AMINO] 2 OXO 1 PYRROLIDINEACETAMIDE; APOMORPHINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; OXIDOPAMINE; PROLYLLEUCYLGLYCINAMIDE; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; APOMORPHINE; BRAIN; DOPAMINE; DOPAMINE AGONISTS; DRUG SYNERGISM; LEVODOPA; MALE; MSH RELEASE-INHIBITING HORMONE; OXIDOPAMINE; PYRROLIDINONES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR;

ANIMALIA;

EID: 0031470206     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00147-2     Document Type: Article

References (48)

1. 3H apomorphine binding sites. Gen. Pharmacol. 14:1983;609-614.
2. Banks W. A., Kastin A. J. Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1 Comparison with morphine . Peptides. 15:1994;23-29.
3. Barbeau A. Potentiation of levadopa effect by intravenous 1-propyl-l-leucyl-glycinamide in man. Lancet. 2:1975;683-685.
4. Barbeau A., Roy M., Gonce M., Labreoque L. Newer therapeutic approaches in Parkinson's disease. Adv. Neurol. 24:1978;433-437.
5. Barbeau A., Roy M., Kastin A. J. Double blind evaluation of oral L-prolyl-L-leucyl-glycine amide in parkinsons disease. Can. Med. Assoc. J. 114:1976;120-122.
6. Bhargava H. N. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats. Peptides. 23:1984;439-444.
7. Celis M. E., Taleisnik S., Walter R. Regulation of formation and proposed structure of the factor inhibiting the release of alpha-MSH. Proc. Natl. Acad. Sci. USA. 68:1971;1428-1433.
8. Chiu S., Paulose C. S., Mishra R. K. Neuroleptic drug-induced dopamine receptor supersensitivity antagonism by L-prolyl-L-leucyl-glycinamide . Science. 214:1981;1261-1262.
9. Chiu S., Paulose C. S., Mishra R. K. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catelepsy and dopamine/neuroleptic receptor bindings. Peptides. 2:1981;105-111.
10. 3H-N-n-propylnorapomorphine to striatal membranes of rats influence of prolyl-leucyl-glycinamide . Pharmacology. 31:1985;241-247.
11. Donnan G. A., Woodhouse D. G., Kaczmarczyk S. J., Holder J. E., Paxinos G., Chilco P. J., Churchyard A. J., Kalnins R. M., Fabinyi G. C. A., Mendelsohn F. A. O. Evidence for plasticity of the dopaminergic system in Parkinsonism. Mol. Neurobiol. 5:1992;421-433.
12. Drucker G. E., Ritzmann R. F., Wichlinski L. J., Engh K., Gordon J. H., Fields J. Z. Prevention and reversal of dopamine receptor supersensitivity by cyclo(leucyl-glycyl) (CLG) Biphasic dose-response curves . Pharmacol. Biochem. Behav. 47:1994;141-145.
13. Ehrensing R. H., Kastin A. J., Larsons P. F., Bishop G. A. Melanocyte stimulating hormone release inhibiting factor-1 and tardive dyskinesia. Dis. Nerv. Syst. 38:1977;303-307.
14. Ehrensing R. H., Kastin A. J., Wurzlow G. F., Michell G. F., Mebane A. H. Improvement in major depression after low subcutaneous doses of MIF-1. J. Affect. Disord. 31:1994;227-233.
15. Fields J. Z., Lee J. M., Gordon J. H., Wichlinski L. J., Ritzmann R. F. The effects of cyclo(leucyl-glycyl) on nigrostriatal dopaminergic supersensitivity - inhibition of apomorphine-induced climbing. Neuropeptides. 16:1990;207-211.
16. Hara C., Kastin A. J. Biphasic effects of MIF-1 and Tyr-MIF-1 on apomorphine-induced stereotypy in rats. Pharmacol. Biochem. Behav. 25:1986;757-761.
17. Heiniger J., Kissling-Albrecht L., Neuenschwander S., Rosli R., Pliska V. Antihaemophilic effect of vasopressin, deamino-(D-arginine)-vasopressin and adrenaline in sheep proposal for an in vivo assay system . Br. J. Psychiatry. 94:1988;279-281.
18. 2 analogues possessing cyclic amino acid residues at the C-terminal position. J. Med. Chem. 29:1986;2100-2104.
19. 2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN. J. Med. Chem. 29:1986;2104-2107.
20. Kastin A. J., Barbeau A. Preliminary clinical trials with MIF in parkinsons disease. Can. Med. Assoc. J. 107:1972;1079-1081.
21. Korczyn, A. D. Parkinson's disease. In: Bloom, F. E.; Kupfer, D. J., Eds. Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995:1479-1984.
22. Kostrzewa R. M., Kastin A. J., Sobrian S. K. Potentiation of apomorphine action in rats by L-prolyl-L-leucyl-glycine amide. Pharmacol. Biochem. Behav. 9:1978;375-378.
23. 1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat. Neuropharmacology. 28:1989;805-810.
24. 2 synergism are unrelated to changes in striatal receptor density. Synapse. 12:1992;14-26.
25. 2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine Parkinsonian rat model. Brain Res. Bull. 28:1992;697-701.
26. Mefford I. N. Application of high performance liquid chromatography with electrochemical detection to neurochemical analysis Measurement of catecholamines, serotonin and metabolites in rat brain . J. Neurosci. Methods. 3:1981;207-224.
27. Mishra R. K., Chiu S., Chiu P., Mishra C. P. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG) A review . Methods Find. Exp. Clin. Pharmacol. 5:1983;203-233.
28. Mishra, R. K.; Chui, S.; Kazmi, S. M. I.; Rajakumar, G.; Johnson, R. L. L-Prolyl-L-leucyl-glycinamide (PLG) and its analogues: clinical implications in extrapyramidal motor disorders and depression. [Anonymous] Drugs of the Future. 11th ed. Barcelona: J. K. Prous Science; 1986:203-7.
29. Mishra R. K., Marshall A. M., Varmuza S. L. Supersensitivity in rat caudate nucleus Effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes . Brain Res. 200:1980;47-57.
30. Mishra R. K., Srivastava L. K., Johnson R. L. Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide. Prog. Neuropsychopharmacol. Biol. Psychiatry. 14:1990;821-827.
31. Mycroft F. J., Bhargava H. N., Wei E. T. Pharmacological activities of the MIF-1 analogues pro-leu-gly, tyr-pro-leu-gly and pareptide. Peptides. 8:1987;1051-1055.
32. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, 2nd ed. 1986;Academic Press Limited, New York.
33. Pliska V. Models to explain dose-response relationships that exhibit a downturn phase. Trends Pharmacol. Sci. 15:1994;178-181.
34. Quock R. M., Lucas T. S., Hartl T. J. Potentiation of apomorphine-induced stereotypies by naloxone and L-propyl-L-leucyl-glycinamide. Pharmacol. Biochem. Behav. 19:1983;49-52.
35. Rajakumar G., Naas F., Johnson R. L., Chiu S., Yu K. L., Mishra R. K. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG). Peptides. 8:1987;855-861.
36. 3H-labeled L-prolyl-L-leucyl-glycinamide in the rat. Neuroendocrinology. 11:1973;92-100.
37. 2 receptor ontogeny. Peptides. 10:1989;35-39.
38. Simpson D. G., Dallal G. E. BUMP A FORTRAN program for identifying dose-response curves subject to downturns . Comput. Biomed. Res. 22:1989;36-43.
39. Smith J. R., Morgan M. The effects of prolyl-leucyl-glycine amide on drug-induced rotation in lesioned rats. Gen. Pharmacol. 13:1982;203-207.
40. 2. J. Med. Chem. 36:1993;256-263.
41. 2 receptor Evidence for modulation of agonist affinity states in bovine striatal membranes . J. Neurochem. 50:1988;960-968.
42. 2 receptor Evidence for modulation of agonist affinity states in bovine striatal membranes . J. Neurochem. 50:1988;960-968.
43. 2. J. Med. Chem. 36:1993;2356-2361.
44. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl. 367:1971;49-68.
45. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;69-93.
46. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;95-122.
47. Xu D. L., Yu W. C., Pan G. B., Chen S. D. Mechanism of action of L-leucyl-glycinamide and its effects on Parkinson's disease. Adv. Neurol. 45:1986;587-590.
48. 2. J. Med. Chem. 31:1988;1430-1436.